Lantern Pharma Inc. Q1 FY2025 earnings call

Clinical Pipeline Progress

• LP-184 Phase 1a trial: Enrollment through cohort 12, expects to complete with 62-65 patients by June 2025; early clinical activity at higher doses; Safety Review Committee backfilled doses 10 and 11; dual fast track designations for glioblastoma and triple-negative breast cancer, plus rare pediatric disease designations; FDA cleared Phase 1b/2 studies in TNBC and drug-resistant NSCLC; investigator-led trial for LP-184 in recurrent bladder cancer planned for Q3 2025.
• HARMONIC Phase 2 trial for LP-300: Enrollment in Japan and Taiwan; ongoing expansion cohort supporting positive trends; updated results expected in Q3.
• Starlight Therapeutics' STAR-001: Phase 1b/2 trial in recurrent GBM anticipated in late 2025; LP-184 has pediatric disease designations with potential priority review vouchers.

AI Platform Advancements

• Radar AI platform expanded to ~200 billion oncology-focused data points; opening up modules to scientific community, starting with BBB permeability prediction tool; AI-powered module for antibody drug conjugate development.

Shareholder Value Maximization

• Maintained disciplined capital management; cash position ~$19.7M as of March 31, 2025; expecting to fund operations for at least 12 months; pursuing additional funding opportunities.

No specific product segment financial performance breakdown by absolute terms and revenue contribution % provided in the transcript.

Forward-looking Statements

• Complete LP-184 Phase 1a trial enrollment in June with data readouts.
• Deliver expanded HARMONIC Trial results including Asian cohort in Q3.
• Initiate FDA cleared Phase 1b/2 trials for LP-184 in TNBC and drug-resistant NSCLC.
• Commercialize initial radar modules to scientific community, starting with BBB permeability tool.
• Strategically advance partnership discussions to accelerate pipeline.

Risks

• Forward-looking statements subject to risks such as clinical trial results, competition, and factors detailed in the annual report on Form 10-K.

Q: On making AI modules commercially available, plans for freemium model and data aggregation.

A: Yes, starting with a freemium type approach to get people used to it; road map to be discussed toward end of quarter or early next quarter; focusing on advancing pipeline and driving tech partnerships.

Q: On HARMONIC trial Asian cohort design.

A: Expansion cohort is randomized, includes U.S. and Asian patients; lead-in cohort had positive results with 86% clinical benefit rate and 43% objective response rate.

Q: On FDA using AI.

A: FDA will likely use AI, but will evaluate in parallel to existing methods; trade-off of cost and speed, with evaluation expected to take at least two years.

Q: On new funds in AI.

A: AI funds will help long-term profile and attract investors, aligning with the company's efforts to open up AI modules.